ALRTF (ALR Technologies SG) Beta: 2.5820 (As of Jun. 25, 2026)


What is ALR Technologies SG Beta?

ALR Technologies SG ALRTF Beta is 2.5820 as of Jun. 25, 2026. The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), ALR Technologies SG's Beta is 2.5820.

ALR Technologies SG  (OTCPK:ALRTF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

ALR Technologies SG Beta Related Terms

ALR Technologies SG Beta Historical Data

* Premium members only.

The historical data trend for ALR Technologies SG's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ALR Technologies SG Beta Chart

ALR Technologies SG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.77 0.66 1.31 1.35 3.08

ALR Technologies SG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.31 1.14 1.35 2.87 3.08

ALRTF vs ALUR, NXL, VVOS: Beta Comparison

For the Medical Devices subindustry, ALR Technologies SG's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ALR Technologies SG Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ALR Technologies SG's Beta distribution charts can be found below:

* The bar in red indicates where ALR Technologies SG's Beta falls into.


ALR Technologies SG Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.5820 mean?
ALR Technologies SG (ALRTF) has a Beta of 2.5820 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for ALR Technologies SG and its competitors.
Is ALR Technologies SG's Beta too high?
ALR Technologies SG's current Beta is 2.5820.
How does ALR Technologies SG's Beta compare to ALUR and NXL?
ALR Technologies SG's Beta of 2.5820 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for ALR Technologies SG and its competitors. ALR Technologies SG's current Beta is 2.5820. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALR Technologies SG stock overvalued right now?
ALR Technologies SG (ALRTF) has a current Beta of 2.5820. The current Beta is 2.5820. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For ALR Technologies SG (ALRTF), the current Beta is 2.5820 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ALR Technologies SG Business Description

Address 9 Raffles Place, No. 26-01, Republic Plaza, Singapore, SGP, 048619
ALR Technologies SG Ltd is a medical device company that focuses on commercializing its Health-e-Connect System. The company is a data management company that developed a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA-compliant Diabetes Solution product that can collect data from BGM and CGM; a patent-pending Predictive A1C algorithm to track treatment success between lab reports; and an FDA-cleared Insulin Dosing Adjustment program. Geographically, it operates in the United States and Singapore.